MedPath

Sorafenib

Generic Name
Sorafenib
Brand Names
Nexavar, Sorafenib Accord
Drug Type
Small Molecule
Chemical Formula
C21H16ClF3N4O3
CAS Number
284461-73-0
Unique Ingredient Identifier
9ZOQ3TZI87
Background

Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.

Indication

Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.

In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.

Associated Conditions
Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
Clinical Trials
Related News

DKN-01 Inhibition in Advanced Liver Cancer

Phase 1
Conditions
Hepatocellular Carcinoma
Interventions
Drug: DKN-01 600 mg
Drug: DKN-01 300 mg
First Posted Date
2018-08-24
Last Posted Date
2020-10-22
Lead Sponsor
Johannes Gutenberg University Mainz
Target Recruit Count
70
Registration Number
NCT03645980
Locations
🇩🇪

Universitätsklinikum Schleswig Holstein Campus Lübeck, Lübeck, Germany

🇩🇪

Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

🇩🇪

Universitätsklinikum Köln, Cologne, Germany

and more 3 locations

Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent to Another Systemic First-line Treatment

Terminated
Conditions
Hepatocellular Carcinoma
Interventions
First Posted Date
2018-08-23
Last Posted Date
2020-08-21
Lead Sponsor
Bayer
Target Recruit Count
3
Registration Number
NCT03644511
Locations
🇩🇪

Many Locations, Multiple Locations, Germany

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

Phase 2
Terminated
Conditions
Thyroid Cancer
Papillary Thyroid Cancer
Follicular Thyroid Cancer
Thyroid Cancer, Medullary
Differentiated Thyroid Cancer
Poorly Differentiated Thyroid Gland Carcinoma
Interventions
First Posted Date
2018-08-14
Last Posted Date
2021-07-14
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
6
Registration Number
NCT03630120
Locations
🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITD

Phase 2
Completed
Conditions
FLT3-ITD Mutation
AML
Interventions
First Posted Date
2018-08-09
Last Posted Date
2020-03-30
Lead Sponsor
The University of Hong Kong
Target Recruit Count
46
Registration Number
NCT03622541
Locations
🇭🇰

The University of Hong Kong, Hong Kong, Hong Kong

Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA)

Phase 2
Completed
Conditions
Hepatocellular Carcinoma
Interventions
Device: NovoTTF-100L(P) device
First Posted Date
2018-07-31
Last Posted Date
2024-11-14
Lead Sponsor
NovoCure Ltd.
Target Recruit Count
25
Registration Number
NCT03606590
Locations
🇨🇿

University Hospital Fakultni Nemocnice Olomouc, Oncology Clinic, Olomouc, Czechia

🇩🇪

Ulm University Hospital, Ulm, Germany

🇫🇷

CHU de Nantes, Nantes Cedex 01, France

and more 5 locations

CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma

Phase 2
Terminated
Conditions
Hepatocellular Carcinoma
Advanced Cancer
Interventions
First Posted Date
2018-07-11
Last Posted Date
2023-01-10
Lead Sponsor
TaiRx, Inc.
Target Recruit Count
12
Registration Number
NCT03582618
Locations
🇨🇳

National Taiwan University Hospital, Taipei, Taiwan

🇨🇳

National Cheng Kung University Hospital, Tainan, Taiwan

🇺🇸

Charleston Hematology Oncology Associates, Charleston, South Carolina, United States

SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC

Phase 2
Completed
Conditions
Hepatocellular Carcinoma
Interventions
First Posted Date
2018-07-06
Last Posted Date
2020-04-09
Lead Sponsor
The University of Hong Kong
Target Recruit Count
15
Registration Number
NCT03578874
Locations
🇭🇰

Queen Mary Hospital, Hong Kong, Hong Kong

Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer

Phase 2
Completed
Conditions
Thyroid Cancer, Anaplastic
Interventions
Procedure: operation
Radiation: External radiation therapy
First Posted Date
2018-06-21
Last Posted Date
2024-04-19
Lead Sponsor
Fujian Medical University
Target Recruit Count
18
Registration Number
NCT03565536
Locations
🇨🇳

Fujian Medical University Union Hospital, FuZhou, Fujian, China

QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine

Phase 1
Withdrawn
Conditions
Hepatocellular Carcinoma Recurrent
Hepatocellular Carcinoma Non-resectable
Interventions
Biological: ETBX-011
Biological: GI-4000
Biological: haNK for infusion
Biological: avelumab
Procedure: SBRT
Biological: Aldoxorubicin hydrochloride
Biological: ETBX-051
Biological: ETBX-061
Biological: GI-6207
Biological: GI-6301
Biological: N-803
First Posted Date
2018-06-20
Last Posted Date
2021-03-18
Lead Sponsor
ImmunityBio, Inc.
Registration Number
NCT03563170
Locations
🇺🇸

Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

Phase 3
Active, not recruiting
Conditions
Childhood Malignant Liver Neoplasm
Hepatoblastoma
Fibrolamellar Carcinoma
Childhood Hepatocellular Carcinoma
Hepatocellular Malignant Neoplasm, Not Otherwise Specified
Interventions
Procedure: Biospecimen Collection
Other: Patient Observation
Procedure: Resection
First Posted Date
2018-05-23
Last Posted Date
2025-03-19
Lead Sponsor
Children's Oncology Group
Target Recruit Count
537
Registration Number
NCT03533582
Locations
🇺🇸

Children's Hospital of Alabama, Birmingham, Alabama, United States

🇺🇸

Providence Alaska Medical Center, Anchorage, Alaska, United States

🇺🇸

Banner Children's at Desert, Mesa, Arizona, United States

and more 202 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy